SUMMARY Fifty consecutive patients with non-ulcer dyspepsia and a Campylobacter associated gastritis (CAG) were randomly assigned to treatment with colloidal bismuth subcitrate (CBS) 240 mg twice daily or placebo, according to a double blind study design. After the blind treatment an 'open' treatment with CBS was started in both groups. Twenty six patients treated with CBS showed a significant reduction in colonisation with Campylobacter pyloni and a significant improvement in the Whitehead gastritis score. No significant changes were recorded in twenty four patients treated with placebo. After an additional course of CBS no further improvement in gastritis score was noted but there was a further reduction in Campylobacter colonisation. CBS did not greatly alter subjective complaints. Subjective complaints were improved in both treatment groups except for nausea and meteorism that improved more in the CBS treated patients. This finding again questions the clinical significance of gastritis and also casts doubt on the clinical relevance of therapeutical measures aimed at eradication of C pylon.
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Reports on the presence of spiral bacteria in the human stomach have appeared sporadically over the last century.' Since the work of Marshall and Warren, however, the possible pathogenetic significance of these organisms on type B (antral) gastritis was appreciated,4 and was confirmed by other investigators.5`Campylobacter pylori is found in 98% of patients with gastritis, in 80% of patients with gastric ulcer and in 90% of patients with duodenal ulcers. In patients with dyspeptic symptoms but normal gastric histology C pylori has also been seen overlying the mucosa but only in small numbers.' About one third of patients referred for upper gastrointestinal endoscopy because of upper abdominal complaints appear not to suffer from peptic ulcers, oesophagitis, active duodenitis, or gastric carcinoma and therefore by definition suffer from socalled non-ulcer dyspepsia. These patients constitute a heterogenous group for which at present no effective therapy is available. It days. In contrast, after 28 days of placebo administration no effect on the percentage of patients with grade 3 gastritis was observed. After 28 days of CBS therapy, however, a significant reduction of grade 3 gastritis was noted. Figure 1 shows the changes in histology of the individual patients. Normalisaton of gastric histology occurred in nine (35%) patients of the CBS group and in one (4%) patient of the placebo group (p=002).
CBS AND C PYLORI PRESENCE Table 2 shows the influence of CBS or placebo on the presence of C pylori after 28 and 56 days of therapy respectively. The percentage of patients with grade 3 presence was reduced from 38 at start of the therapy to 12 after 28 days of CBS and a further reduction was obtained after 56 days of therapy. No such effect was found in patients given placebo treatment. Grade 3 presence was significantly reduced after the open CBS treatment course in these patients. Figure 2 shows the changes of the individual patients.
In one patient of the CBS group endoscopy after CBS revealed a small gastric ulcer located at the angulus, this patient did not show any improvement of gastritis score. After the additional course of CBS it was healed. One patient of the placebo group showed a duodenal ulcer after 28 days of placebo therapy that healed after CBS.
CBS AND SYMPTOMS
As shown in Table 4 overall assessment of subjective changes of complaints revealed improvement in half of the patients given CBS, 30% recorded no change, 16% became free of complaints and one patient noted worsening of his complaints as a result of the peptic ulcer. Seventy one per cent of the patients given placebo recorded improvement, whereas none Fig. 2 group.bmj.com on July 7, 2017 -Published by http://gut.bmj.com/ Downloaded from became free of complaints. The remainder noted no change. There appeared to be no significant difference in overall assessment between both groups. There was no significant difference between the five symptoms that were recorded separately in both groups. All symptoms showed the same improvement (Table 5 ). Figure 3 , however, shows that the percentual improvement of nausea and meteorism in the CBS group was better.
Discussion
In the literature there are several reports on the effect of bismuth on gastritis and Campylobacter pylori in patients with non-ulcer dyspepsia. 24 The results of these studies show that there is a resolution of gastritis after suppresson or eradication of C pylori. The majority of these studies, however, failed to provide exact information on inclusion criteria, standardisation of gastritis and C pylori scores.
In addition the best available data on the treatment of Campylobacter associated gastritis, especially with bismuth, have been based on non-controlled trials.s Bismuth salts have two effects: they are bactericidal for C pylori and they can protect the gastric mucosa against erosive properties of alcohol and aspirin. Bismuth may protect the mucosa from gastric acid with subsequent resolution of gastritis with alteration of the gastric milieu, which is unfavourable for C pylori. Sucralfate has no bactericidal effects on C pylori, and it has no beneficial effect on histologically confirmed gastritis.26 This suggests that it is the antimicrobial activity of bismuth that is important. C pylori produces a protease which undermines the integrity of the mucus layer. Therefore, because of its bactericidal effect bismuth may have an indirect favourable effect on gastric mucosa." McNulty et al reported on a double blind study of bismuthsalicylate,21 77-8% of their patients receiving bismuth were cleared of Cpylori after the treatment. This clearance was accompanied with a significant improvement of gastritis score.
The results of our study also show that CBS effectively reduces C pylori colonisation of gastric mucosa and significantly improves signs of gastritis. Complete disappearance of the micro-organism, however, only occurred in a small number of patients, which possibly explains the high percentage of recurrence reported in the literature.' " In addition we showed a positive influence of administration of CBS on subjective complaints which, however, largely appeared to be the result of a placebo effect.
Two pertinent aspects of our observations deserve special consideration. First, at day 28 a parallelism in reduction of C pylori presence and gastritis scores was seen in the CBS treated patients, suggestive of a 
